Dicerna Pharmaceuticals
Dicerna
Scientific Publications
Molecular Therapy: RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade, Nov. 2018.
Molecular Therapy: Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria, Aug. 2018.
Molecular Cancer Therapeutics: β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models, Aug. 2018.
Molecular Therapy: Inhibition of Glycogen Synthase II with RNAi Prevents Liver Injury in Mouse Models of Glycogen Storage Diseases, July 2018.
Hepatology: Targeting β-catenin in hepatocellular cancers induced by coexpression of mutant β-catenin and K-Ras in mice, May 2018.
Molecular Cancer Therapeutics: Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin, Mar. 2017.
Molecular Therapy: Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1, Jan. 2016.
Molecular Therapy: Knockdown of β-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo, Oct. 2013.
